CF PharmTech Shares Rise Nearly 9% in Morning Trading as Core Management Voluntarily Extends Lock-Up Period

Deep News10-13

CF PharmTech (02652) saw its shares climb nearly 9% in morning trading. As of press time, the stock was up 8.91%, trading at HK$6.665, with a turnover of HK$26.2328 million.

According to the latest data from the Hong Kong Stock Exchange, on October 6, Chairman and Chief Executive Officer Liang Wenqing increased his holdings by 19,300 shares of CF PharmTech at a price of HK$6.9216 per share, for a total amount of approximately HK$133,600. Following the increase, his latest shareholding stood at approximately 60.7165 million shares, representing an 18.74% stake.

It is worth noting that Chairman, Executive Director and Chief Executive Officer Dr. Liang Wenqing and the company's co-founder, Executive Director and Chief Scientific Officer Dr. Li Li recently made voluntary commitments to further extend the lock-up period on their shares by 6 months after the original lock-up period expires on October 7. The extended lock-up period runs from October 8, 2026 to April 7, 2027.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment